Pharmacogenomics in psychiatry : the relevance of receptor and transporter polymorphisms

REYNOLDS, Gavin P., MCGOWAN, Olga O. and DALTON, Caroline F. (2014). Pharmacogenomics in psychiatry : the relevance of receptor and transporter polymorphisms. British Journal Of Clinical Pharmacology, 77 (4), 654-672.

Full text not available from this repository.
Official URL: http://dx.doi.org/10.1111/bcp.12312
Link to published version:: https://doi.org/10.1111/bcp.12312
Related URLs:

    Abstract

    The treatment of severe mental illness, and of psychiatric disorders in general, is limited in its efficacy and tolerability. There appear to be substantial interindividual differences in response to psychiatric drug treatments that are generally far greater than the differences between individual drugs; likewise, the occurrence of adverse effects also varies profoundly between individuals. These differences are thought to reflect, at least in part, genetic variability. The action of psychiatric drugs primarily involves effects on synaptic neurotransmission; the genes for neurotransmitter receptors and transporters have provided strong candidates in pharmacogenetic research in psychiatry. This paper reviews some aspects of the pharmacogenetics of neurotransmitter receptors and transporters in the treatment of psychiatric disorders. A focus on serotonin, catecholamines and amino acid transmitter systems reflects the direction of research efforts, while relevant results from some genome-wide association studies are also presented. There are many inconsistencies, particularly between candidate gene and genome-wide association studies. However, some consistency is seen in candidate gene studies supporting established pharmacological mechanisms of antipsychotic and antidepressant response with associations of functional genetic polymorphisms in, respectively, the dopamine D2 receptor and serotonin transporter and receptors. More recently identified effects of genes related to amino acid neurotransmission on the outcome of treatment of schizophrenia, bipolar illness or depression reflect the growing understanding of the roles of glutamate and γ-aminobutyric acid dysfunction in severe mental illness. A complete understanding of psychiatric pharmacogenomics will also need to take into account epigenetic factors, such as DNA methylation, that influence individual responses to drugs.

    Item Type: Article
    Research Institute, Centre or Group - Does NOT include content added after October 2018: Biomolecular Sciences Research Centre
    Identification Number: https://doi.org/10.1111/bcp.12312
    Page Range: 654-672
    Depositing User: Louise Vickers
    Date Deposited: 05 Nov 2014 12:49
    Last Modified: 13 Jun 2017 13:20
    URI: http://shura.shu.ac.uk/id/eprint/8591

    Actions (login required)

    View Item View Item

    Downloads

    Downloads per month over past year

    View more statistics